Meeting
2023 ASCO Annual Meeting
Clinical and biological activity of FLX475, an oral CCR4 antagonist, in advanced cancer.
Authors
Dirk G. Brockstedt
RAPT Therapeutics, Inc., South San Francisco, CA
Dirk G. Brockstedt , Adam Grant , Juraj Adamik , Damian Trujillo , Rakesh Kumar Goyal , William Ho , Shoji Ikeda , Qingfeng Zhu , Robert A. Anders , Mohsen Sabouri , Paul D Kassner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Clinical Trial Registration Number
NCT03674567
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2625)
DOI
10.1200/JCO.2023.41.16_suppl.2625
Abstract #
2625
Poster Bd #
467
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.
First Author: John D. Powderly II
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I/II dose escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.
First Author: William Ho
Poster
2023 ASCO Annual Meeting
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
First Author: Nicholas Coupe
Poster
2023 ASCO Annual Meeting
A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.
First Author: Jordi Rodon Ahnert